Clinical development of atypical antipsychotics

Good Clinical Practice Journal

Volumn 8, Issue 7, 2001, Pages 20-26

  Siegfried, K ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SERTINDOLE; ZIPRASIDONE;

BINDING KINETICS; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG APPROVAL; DRUG EFFICACY; DRUG LEGISLATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOOD CLINICAL PRACTICE; HUMAN; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MEDICAL ETHICS; MENTAL DISEASE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; PSYCHOLOGIC ASSESSMENT; RECURRENT DISEASE; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034922371     PISSN: 13500961     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. The mechanism of action of novel antipsychotic drugs
2. Dimensions of outcome with clozapine
3. The concept of an atypical antipsychotic drug
4. Typical and atypical differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons
5. The new generation of antipsychotic drugs: How atypical are they?
6. Olanzapine versus placebo and haloperidol. Acute phase of the North American double-blind olanzapine trial
7. ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter placebo-controlled trial in patients with schizophrenia
8. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
9. Risperidone in the treatment of schizophrenia
10. A controlled double-blind multicentre trial of high dose amisulpiride vs. haloperidol in acute psychotic states
11. Controlled, dose-response study of sertindole and haloperidol in treatment of schizophrenia
12. Dementia praecox oder die Gruppe der Schizophrenien
13. Symptoms of schizophrenia. Methods, meaning, and mechanisms
14. The risk of medication-free research
15. Medication-free research with schizophrenic patients. A European perspective
16. The positive and negative syndrome scale (PANSS) for schizophrenia
17. The brief psychiatric rating scale
18. Clinical global impressions
19. Positive and negative symptoms
20. Regional cerebral blood flow and subsyndromes of schizophrenia
21. Depressive signs and symptoms in schizophrenia. A prospective blinded trial of olanzapine and haloperidol
22. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpiride
23. Amisulpiride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
24. Subjective effects of neuroleptics predict compliance
25. On the heterogeneity of schizophrenia
26. Negative symptoms in schizophrenia: Considerations for clinical trials. Working group on negative symptoms in schizophrenia
27. Deficit and non-deficit forms of schizophrenia: The concept
28. Neurocognitive deficits in schizophrenia
29. Neuropsychological predictors of treatment efficacy and one-year outcome in schizophrenia
30. Improvement in cognitive functions and psychiatric symptoms in treatment refractory schizophrenic patients receiving clozapine